• Login

Real, Joana and Miranda, Caroline and Olofsson, Charlotta S. and Smith, Paul A. (2018) Lipophilicity predicts the ability of nonsulphonylurea drugs to block pancreatic beta-cell KATP channels and stimulate insulin secretion: statins as a test case. Endocrinology, Diabetes & Metabolism, 1 (2). e00017/1-e00017/10. ISSN 2002-7354

Preview

PDF - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader Available under Licence Creative Commons Attribution Non-commercial. Download (1MB) | Preview

Abstract

Aims

KATP ion channels play a key role in glucose‐stimulated insulin secretion. However, many drugs block KATP as “off targets” leading to hyperinsulinaemia and hypoglycaemia. As such drugs are often lipophilic, the aim was to examine the relationship between drug lipophilicity (P) and IC50 for KATP block and explore if the IC50's of statins could be predicted from their lipophilicity and whether this would allow one to forecast their acute action on insulin secretion.

Materials and methods

A meta‐analysis of 26 lipophilic, nonsulphonylurea, blockers of KATP was performed. From this, the IC50's for pravastatin and simvastatin were predicted and then tested experimentally by exploring their effects on KATP channel activity via patch‐clamp measurement, calcium imaging and insulin secretion in murine beta cells and islets.

Results

Nonsulphonylurea drugs inhibited KATP channels with a Log IC50 linearly related to their logP. Simvastatin blocked KATP with an IC50 of 25 nmol/L, a value independent of cytosolic factors, and within the range predicted by its lipophilicity (21‐690 nmol/L). 10 μmol/L pravastatin, predicted IC50 0.2‐12 mmol/L, was without effect on the KATP channel. At 10‐fold therapeutic levels, 100 nmol/L simvastatin depolarized the beta‐cell membrane potential and stimulated Ca2+ influx but did not affect insulin secretion; the latter could be explained by serum binding.

Conclusions

The logP of a drug can aid prediction for its ability to block beta‐cell KATP ion channels. However, although the IC50 for the block of KATP by simvastatin was predicted, the difference between this and therapeutic levels, as well as serum sequestration, explains why hypoglycaemia is unlikely to be observed with acute use of this statin.

Actions (Archive Staff Only)

Edit View